IPH 4102

Drug Profile

IPH 4102

Alternative Names: Anti-KIR3DL2 cytotoxic mAb; IPH 4101; IPH41; IPH4102

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Genoa
  • Developer Innate Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action KIR3DL2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cutaneous T cell lymphoma

Most Recent Events

  • 01 Nov 2017 Assistance Publique Hopitaux De Marseille plans a clinical trial for Spondyloarthritis in patients and volunteers in France in November 2017 (NCT03322618)
  • 16 Oct 2017 Final efficacy data from a phase I trial in Cutaneous T-cell lymphoma released by Innate Pharma
  • 15 Jun 2017 Updated efficacy, pharmacodynamics and adverse events data from a phase I trial in Cutaneous T-cell lymphoma presented at the International Conference on Malignant Lymphoma (ICML-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top